Drug intelligence / Profile preview

GB002

Development stage: Unknown
Lead developer: Gossamer Bio
Modality: Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

GB002 is an inhaled recombinant polypeptide developed by Gossamer Bio, Zhejiang Echon Biopharm Limited, Pulmokine, and Gilead. It functions as a platelet-derived growth factor (PDGF) receptor kinase inhibitor, primarily intended for the treatment of Pulmonary Arterial Hypertension (PAH). The drug is designed to be a disease-modifying treatment by inhibiting the cellular proliferation that underlies the pathology of PAH.

Other names: GB002 Recombinant Peptide Inhalation SolutionGB-002 Recombinant Peptide Inhalation SolutionGB 002 Recombinant Peptide Inhalation Solution

Targets

PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on GB002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB002.

Explore the full profile